原发性肺印戒细胞癌1例诊治与文献报道
Primary Signet-Ring Cell Carcinoma of the Lung: A Case Report: Diagnosis, Treatment and Literature Report
DOI: 10.12677/ACM.2022.12111501, PDF,   
作者: 王雪岩：西安医学院，陕西 西安；雷光焰：陕西省肿瘤医院胸外科，陕西 西安；闫 柯：陕西省人民医院肿瘤外科，陕西 西安
关键词: 病例报告；肺；印戒细胞癌；阿来替尼；Case Report； Lung； Signet-Ring Cell Carcinoma； Alectinib
摘要: 印戒细胞癌(signet-ring cell carcinoma, SRCC)是一种低分化腺癌亚型，具有侵袭性，通常发生在胃肠道、前列腺或乳腺。本文描述了1例陕西省人民医院原发性肺SRCC的诊断、病理和治疗策略，以提高我们对这种肿瘤的认识。根据本文提供的信息，如果早期诊断并积极治疗，原发性肺部SRCC患者可以存活很长时间。然而，由于关于原发性肺SRCC的报道有限，还需要更多研究。
Abstract: Signet-ring cell carcinoma (SRCC) is a poorly differentiated adenocarcinoma subtype, which is ag-gressive and usually occurs in the gastrointestinal tract, prostate or breast. This paper describes the diagnosis, pathology and treatment strategy of a case of primary pulmonary SRCC in Shaanxi Provincial People’s Hospital, in order to improve our understanding of this tumor. According to the information presented here, patients with primary pulmonary SRCC can survive for a long time if diagnosed early and treated aggressively. However, due to limited reports on primary lung SRCC, more studies are needed.
文章引用：王雪岩, 雷光焰, 闫柯. 原发性肺印戒细胞癌1例诊治与文献报道[J]. 临床医学进展, 2022, 12(11): 10418-10422. https://doi.org/10.12677/ACM.2022.12111501

参考文献

[1] Wang, Y., Wang, Y., Li, J. and Che, G. (2020) Primary Signet-Ring Cell Carcinoma of the Lung: A Report of Seven Cases. Thoracic Cancer, 11, 3015-3019. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, T., Shen, B., Wang, L. and Liu, F. (2020) Primary Signet Ring Cell Carcinoma of the Breast: A Rare Entity with Unique Biological Behav-ior—A Clinical Study Based on Pure Signet Ring Cell Carcinoma Cohort. Pathology Research and Practice, 216, Article ID: 152948. [Google Scholar] [CrossRef] [PubMed]
[3] Ou, S.H., Ziogas, A. and Zell, J.A. (2010) Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 5, 420-427. [Google Scholar] [CrossRef] 
[4] Wu, S.G., Chen, X.T., Zhang, W.W., et al. (2018) Survival in Signet Ring Cell Carcinoma Varies Based on Primary Tumor Location: A Surveillance, Epidemiology, and End Results Database Analysis. Expert Review of Gastroenterology & Hepatology, 12, 209-214. [Google Scholar] [CrossRef] [PubMed]
[5] Testori, A., Perroni, G., Carlo, C., et al. (2021) Primary Signet-Ring Cell Carcinoma of the Lung in an HIV-Positive Patient. Thoracic Cancer, 12, 1122-1125. [Google Scholar] [CrossRef] [PubMed]
[6] Castro, C.Y., Moran, C.A., Flieder, D.G. and Suster, S. (2001) Primary Signet Ring Cell Adenocarcinomas of the Lung: A Clinicopathological Study of 15 Cases. Histopathology, 39, 397-401. [Google Scholar] [CrossRef] [PubMed]
[7] Boland, J.M., Wampfler, J.A., Jang, J.S., et al. (2014) The American Journal of Surgical Pathology, 38, 1681-1688. [Google Scholar] [CrossRef] 
[8] Terada, T. (2012) Primary Signet-Ring Cell Carcinoma of the Lung: A Case Report with an Immunohistochemical Study. International Journal of Clinical and Experimental Pa-thology, 5, 171-174.
[9] Danzinger, S., Köstler, W.J., Funovics, M., et al. (2019) Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy. Case Reports in Obstetrics and Gynecology, 2019, Article ID: 9461579. [Google Scholar] [CrossRef] [PubMed]
[10] Yoshida, A., Tsuta, K., Watanabe, S., et al. (2011) Frequent ALK Re-arrangement and TTF-1/p63 Co-Expression in Lung Adenocarcinoma with Signet-Ring Cell Component. Lung Cancer, 72, 309-315. [Google Scholar] [CrossRef] [PubMed]
[11] Hao, Y.Q., Tang, H.P. and Liu, H.Y. (2015) Primary Sig-net-Ring Cell Carcinoma of the Lung Treated with Crizotinib: A Case Report. Oncology Letters, 9, 2205-2207. [Google Scholar] [CrossRef] [PubMed]
[12] Adderley, H., Blackhall, F.H. and Lindsay, C.R. (2019) KRAS-Mutant Non-Small Cell Lung Cancer: Converging Small Molecules and Immune Checkpoint Inhibition. EBioMedicine, 41, 711-716. [Google Scholar] [CrossRef] [PubMed]
[13] Takeda, M., Sakai, K., Takahama, T., et al. (2019) New Era for Next-Generation Sequencing in Japan. Cancers (Basel), 11, Article No. 742. [Google Scholar] [CrossRef] [PubMed]
[14] Tsuta, K., Ishii, G., Yoh, K., et al. (2004) Primary Lung Carcinoma with Signet-Ring Cell Carcinoma Components: Clinicopathological Analysis of 39 Cases. The American Journal of Sur-gical Pathology, 28, 868-874. [Google Scholar] [CrossRef] [PubMed]
[15] Pezzuto, A., Terzo, F., Graziani, M.L., et al. (2017) Lung Cancer Requires Multidisciplinary Treatment to Improve Patient Survival: A Case Report. Oncology Letters, 14, 3035-3038. [Google Scholar] [CrossRef] [PubMed]
[16] Soda, M., Choi, Y.L., Enomoto, M., et al. (2007) Identifica-tion of the Transforming EML4-ALK Fusion Gene in Non-Small-Cell Lung Cancer. Nature, 448, 561-566. [Google Scholar] [CrossRef] [PubMed]
[17] Rikova, K., Guo, A., Zeng, Q., et al. (2007) Global Survey of Phos-photyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer. Cell, 131, 1190-1203. [Google Scholar] [CrossRef] [PubMed]
[18] Solomon, B.J., Mok, T., Kim, D.W., et al. (2014) First-Line Crizo-tinib versus Chemotherapy in ALK-Positive Lung Cancer. The New England Journal of Medicine, 371, 2167-2177. [Google Scholar] [CrossRef] 
[19] Hida, T., Nokihara, H., Kondo, M., Kim, Y.H., et al. (2017) Alec-tinib versus Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Ran-domised Phase 3 Trial. The Lancet, 390, 29-39. [Google Scholar] [CrossRef] 
[20] Peters, S., Camidge, D.R., Shaw, A.T., Gadgeel, S., Ahn, A.S., et al. (2017) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. The New Eng-land Journal of Medicine, 377, 829-838. [Google Scholar] [CrossRef] 
[21] Chen, H., Lin, C., Peng, T., et al. (2020) Metformin Reduces HGF-Induced Resistance to Alectinib via the Inhibition of Gab1. Cell Death & Disease, 11, Article No. 111. [Google Scholar] [CrossRef] [PubMed]

为你推荐